Plan Overview

A Data Management Plan created using DMPTool

DMP ID: https://doi.org/10.48321/D1F636

Title: Neurodevelopmental effects of embryonic exposure to psychotropic medications in real-world mixtures

Creator: Dena Weinberger - ORCID: 0000-0002-9973-5685

Affiliation: Murray State University (murraystate.edu)

Funder: National Institutes of Health (nih.gov)

Funding opportunity number: PAR-21-255


Template: NIH-Default DMSP

Project abstract:

Wide ranges of drugs with overlapping targets in the nervous system contaminate drinking water sources. Psychotropic medications are among the most commonly prescribed drugs in the U.S., and a significant portion of these drug residues are discharged into the receiving water bodies. These drug residues eventually reach the drinking water, cross maternal biological barriers, and can alter the embryonic nervous system. Exposure of zebrafish embryos to specific combinations of drugs has resulted in nervous system abnormalities and misexpression of genes implicated in autism, Alzheimer’s, and schizophrenia. Thus, chronic exposure to sub-therapeutic doses of these drugs represents a viable risk to human mental health. With the prevalence of such disorders ever-increasing, so does the urgency of understanding how environmental exposure increases risk. This proposal addresses the long-term research goals of elucidating the molecular mechanisms underlying the environmental risks for neuropsychiatric disorders while identifying genes that contribute to normal nervous system development. The hypothesis being tested is that developmental exposure to low levels of psychoactive drugs in environmentally-relevant mixtures drives abnormal gene expression and ultimately affects nervous system function. This proposed research will use bioinformatics and predictive analytics to identify candidate genes from RNA-Seq data generated following exposure of larval zebrafish to environmentally relevant levels of psychoactive drugs found in drinking water source bodies. As a measure the functional consequences of this
type of exposure, on a battery of larval behaviors that are disrupted in neurodevelopmental disorder models will be tested following drug exposure. The next phase of the current proposal will use quantitative RT-PCR and in situ hybridization to quantify and explore nervous system-specific changes in gene expression following drug exposure. By raising zebrafish in dosed water as a proxy for prenatal human exposure through contaminated drinking water, these experiments will identify sensitive behaviors and genes that are expressed in developing neural tissues. The differential expression of each of these genes individually may have minor effects on the organism, and that the summative changes in gene expression are likely complex and varied. The final phase of this proposed research will develop a genetic loss-of-function model for one of the genes that was downregulated following exposure and evaluate the effect of this loss on behavior.

Start date: 09-01-2023

End date: 08-31-2026

Last modified: 05-10-2023

Copyright information:

The above plan creator(s) have agreed that others may use as much of the text of this plan as they would like in their own plans, and customize it as necessary. You do not need to credit the creator(s) as the source of the language used, but using any of the plan's text does not imply that the creator(s) endorse, or have any relationship to, your project or proposal
Neurodevelopmental effects of embryonic exposure to psychotropic medications in real-world mixtures

Data Type

**Types and amount of scientific data expected to be generated in the project:** Summarize the types and estimated amount of scientific data expected to be generated in the project.

Describe data in general terms that address the type and amount/size of scientific data expected to be collected and used in the project (e.g., 256-channel EEG data and fMRI images from ~50 research participants). Descriptions may indicate the data modality (e.g., imaging, genomic, mobile, survey), level of aggregation (e.g., individual, aggregated, summarized), and/or the degree of data processing that has occurred (i.e., how raw or processed the data will be).

This project will produce experimental data from the following methods: video tracking behavior, real-time quantitative polymerase chain reaction, and light microscopy. Data will be collected from a minimum of three independent experiments, with each experiment consisting of multiple groups: exposed vs. control or wild-type (retreg1+/+), heterozygous (retreg1+-), and knockout (retreg1-/-), from these developmental stages: 2-3 days old, 5-6 days old, 17, and 30 days old. The total size of the data collected in this project is projected to be 100 GB.

We expect to generate the following data file types during this project: images (.TIFF), tabular (.CSV and .XLS), and video (.MP4 and H.264 AVC).

Raw data files will be analyzed to generate CSV files containing quantifications of behaviors and gene expression counts, and to enable statistical analysis.

**Scientific data that will be preserved and shared, and the rationale for doing so:** Describe which scientific data from the project will be preserved and shared and provide the rationale for this decision.

In this proposed project, the cleaned, item-level spreadsheet data for all variables will be shared openly, along with example quantifications and transformations from initial raw data. Final files used to generate specific analyses to answer the Specific Aims and related results will also be shared. The rationale for sharing only cleaned data is to foster ease of data reuse.

Metadata, other relevant data, and associated documentation: Briefly list the metadata, other relevant data, and any associated documentation (e.g., study protocols and data collection instruments) that will be made accessible to facilitate interpretation of the scientific data.

To facilitate interpretation of the data, protocols DOIs will be created and shared from protocols.io.

**Related Tools, Software and/or Code**
State whether specialized tools, software, and/or code are needed to access or manipulate shared scientific data, and if so, provide the name(s) of the needed tool(s) and software and specify how they can be accessed.

Imaging data will be made available in tif format, and video data will be made available in mp4 format and will not require the use of specialized tools to be accessed or manipulated.

Standards

State what common data standards will be applied to the scientific data and associated metadata to enable interoperability of datasets and resources, and provide the name(s) of the data standards that will be applied and describe how these data standards will be applied to the scientific data generated by the research proposed in this project. If applicable, indicate that no consensus standards exist.

Data will be stored in common and open formats, such as csv for our behavioral data. Information needed to make use of this data along with references to the sources of those standardized names and metadata items will be included wherever applicable.

Data Preservation, Access, and Associated Timelines

Repository where scientific data and metadata will be archived: Provide the name of the repository(ies) where scientific data and metadata arising from the project will be archived; see Selecting a Data Repository.

Data described above in the "data to be shared" section will be deposited into Murray State University's Digital Commons.

How scientific data will be findable and identifiable: Describe how the scientific data will be findable and identifiable, i.e., via a persistent unique identifier or other standard indexing tools.

Murray State University's Digital Commons provides searchable study-level metadata for dataset discovery. [Repository] assigns DOIs as persistent identifiers and has a robust preservation plan to ensure long-term access. Data will be discoverable online through standard web search of the study-level metadata as well as the persistent pointer from the DOI to the dataset. We will include ORCID iDs for people, DOIs for outputs (e.g., datasets, protocols), and Research Resource IDentifiers (RRIDs) for resources as much as possible to make data identifiable and findable.

When and how long the scientific data will be made available: Describe when the scientific data will be made available to other users (i.e., no later than time of an associated publication or end of the performance period, whichever comes first) and for how long data will be available.
All scientific data generated from this project will be made available as soon as possible, and no later than the
time of publication or the end of the funding period, whichever comes first. The duration of preservation and
sharing of the data will be a minimum of 10 years after the funding period.

**Access, Distribution, or Reuse Considerations**

Factors affecting subsequent access, distribution, or reuse of scientific data NIH expects that in
drafting Plans, researchers maximize the appropriate sharing of scientific data. Describe and justify
any applicable factors or data use limitations affecting subsequent access, distribution, or reuse of
scientific data related to informed consent, privacy and confidentiality protections, and any other
considerations that may limit the extent of data sharing. See [Frequently Asked Questions](#) for
eamples of justifiable reasons for limiting sharing of data.

There are no anticipated factors or limitations that will affect the access, distribution or reuse of the scientific
data generated by the proposal.

**Whether access to scientific data will be controlled:** State whether access to the scientific data will
be controlled (i.e., made available by a data repository only after approval).

Controlled access will not be used. The data that is shared will be shared by unrestricted download.

**Protections for privacy, rights, and confidentiality of human research participants:**
If generating scientific data derived from humans, describe how the privacy, rights, and
confidentiality of human research participants will be protected (e.g., through de-identification,
Certificates of Confidentiality, and other protective measures).

These experiments do not use human data.

**Oversight of Data Management and Sharing**

Describe how compliance with this Plan will be monitored and managed, frequency of oversight, and
by whom at your institution (e.g., titles, roles).

Lead PI D.R. Weinberger, ORCID: 0000000299735685, will be responsible for the day-to-day oversight of
lab/team data management activities and data sharing.
Planned Research Outputs

**Data paper - "Neurodevelopmental effects of embryonic exposure to psychotropic medications in real-world mixtures"

Behavior data

**Data paper - "Regulator of autophagy 1 loss-of-function affects larval behavior"

**Data paper - "Developmental exposure to psychotropic drugs in mixture alters gene expression patterns in the brain"

---

**Planned research output details**

<table>
<thead>
<tr>
<th>Title</th>
<th>Type</th>
<th>Anticipated release date</th>
<th>Initial access level</th>
<th>Intended repository(ies)</th>
<th>Anticipated file size</th>
<th>License</th>
<th>Metadata standard(s)</th>
<th>May contain sensitive data?</th>
<th>May contain PII?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurodevelopmental effects of embryonic exposure to psychotropic ...</td>
<td>Data paper</td>
<td>Unspecified</td>
<td>Open</td>
<td>None specified</td>
<td>None specified</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Regulator of autophagy 1 loss-of-function affects larval behavior</td>
<td>Data paper</td>
<td>Unspecified</td>
<td>Open</td>
<td>None specified</td>
<td>None specified</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Developmental exposure to psychotropic drugs in mixture alters gene</td>
<td>Data paper</td>
<td>Unspecified</td>
<td>Open</td>
<td>None specified</td>
<td>None specified</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>